# Identify Effective Doses of SHR7280 Tablets in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART)

> **NCT05082233** · PHASE2 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 85 (actual)

## Conditions studied

- Female Subjects Undergoing COH in ART to Prevent Early Ovulation

## Interventions

- **DRUG:** SHR7280 tablets

## Key facts

- **NCT ID:** NCT05082233
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-06
- **Primary completion:** 2023-08-03
- **Final completion:** 2023-08-03
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2024-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05082233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05082233, "Identify Effective Doses of SHR7280 Tablets in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05082233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*